NCCN 指南®洞察：免疫治疗相关毒性的管理，版本 2.2024。
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.
机构信息
1Fred Hutchinson Cancer Center.
2University of Michigan Rogel Cancer Center.
出版信息
J Natl Compr Canc Netw. 2024 Nov;22(9):582-592. doi: 10.6004/jnccn.2024.0057.
The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell-engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.
NCCN 免疫治疗相关毒性管理指南旨在为肿瘤临床医生提供指导，以处理癌症免疫治疗可能出现的广泛且具有潜在致命性的毒性。该指南涉及免疫检查点抑制剂、嵌合抗原受体 T 细胞疗法和淋巴细胞激动剂（包括 T 细胞结合双特异性抗体）相关的免疫相关不良事件。这些 NCCN 指南见解强调了最近与癌症免疫治疗相关新兴毒性管理相关的指南更新。
Zotero 插件